What is Vivace Therapeutics worth?
$125.0Mlast known valuation
Vivace Therapeutics last raised $35.0M in its Later Stage VC (Series D) (Feb 2025).
Free account
See the evidence behind this price
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Vivace Therapeutics
Create free account
No card required
Funding history
4 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Feb 2025 | Later Stage VC (Series D) | $35.0M | ▮ | ▮ |
| Dec 2020 | Early Stage VC | $30.0M | ▮ | ▮ |
| May 2017 | Early Stage VC | $8.0M | ▮ | ▮ |
| Jan 2015 | Early Stage VC | $5.0M | ▮ | ▮ |
How Vivace Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Vivace Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- What is Vivace Therapeutics worth?
- Vivace Therapeutics's last known valuation is $125.0M.
- How much has Vivace Therapeutics raised?
- Vivace Therapeutics has raised $105.0M in total funding across 4 recorded rounds.
- When did Vivace Therapeutics last raise?
- Vivace Therapeutics last raised in Feb 2025 (Later Stage VC (Series D)), raising $35.0M.